Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / ADS
-
Number of holders
-
24
-
Total 13F shares, excl. options
-
10.4M
-
Shares change
-
-1.82M
-
Total reported value, excl. options
-
$116M
-
Value change
-
-$33.8M
-
Number of buys
-
9
-
Number of sells
-
-11
-
Price
-
$11.85
Significant Holders of Silence Therapeutics plc - ADS (SLN) as of Q2 2022
28 filings reported holding SLN - Silence Therapeutics plc - ADS as of Q2 2022.
Silence Therapeutics plc - ADS (SLN) has 24 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 10.4M shares
.
Largest 10 shareholders include Lombard Odier Asset Management (USA) Corp (3.77M shares), Deep Track Capital, LP (952K shares), Frazier Life Sciences Management, L.P. (881K shares), BVF INC/IL (667K shares), GOLDMAN SACHS GROUP INC (660K shares), AXA S.A. (642K shares), Consonance Capital Management LP (634K shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (565K shares), GREAT POINT PARTNERS LLC (401K shares), and Point72 Asset Management, L.P. (250K shares).
This table shows the top 24 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.